Investing in DURECT Corporation (DRRX)  ➔  Intrinsic value

Prev. close$1.71 
ModelValueUpside
Chepakovich$0.16-91%
Graham-Dodd$0.15-91%
Graham$0.07-96%
Previous Close$1.71  
Valuation MethodValuePotential 
Chepakovich Model$0.16-91%recalculate
Graham-Dodd$0.15-91%recalculate
Graham Formula$0.07-96%recalculate

Latest news

Company description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; Gilead Sciences, Inc; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.